Background. E5564, a competitive lipid A antagonist, inhibits endotoxin-stimulated inflammation and is under study in patients with sepsis.
of lipid A-stimulated inflammatory mediator release during severe gram-negative bacterial sepsis [19, 20] , such as direct inactivation of the lipid A region of endotoxin by antibodies [19, 20] and competitive inhibition by lipid A analogues [21] [22] [23] .
Although early synthetic lipid A analogues showed anti-inflammatory activity during in vitro testing with bacteria and during in vivo testing with endotoxin challenge, they were not effective during in vivo bacterial challenges [24] [25] [26] [27] [28] [29] [30] . In contrast, E5531, an analogue derived from Rhodobacter bacteria and a naturally occurring lipid A antagonist, demonstrated substantial antagonistic activity against endotoxins produced by a range of pathogenic bacteria, with few agonistic effects [31] . E5531 inhibited the release of cytokines, oxygen free radicals, and endothelial selectin molecules and prevented mitogen-response activation in mice, resulting in improved survival after lethal endotoxin challenge [31] [32] [33] . In healthy humans, E5531 inhibited the release of tumor necrosis factor (TNF)-a into the bloodstream and abolished almost all of the septic-like physiological responses after safe, low-dose endotoxin chal- lenges [34] . In mice made sensitive to endotoxin with bacillus Calmette-Guérin (BCG), E5531 worked additively with antibiotics to improve survival after viable bacterial challenge [31] . Another lipid A analogue, E5564, has been shown to have in vitro and in vivo activity comparable to that of E5531 [35] , suppressing rodent and human cytokine responses to endotoxin stimulation in vitro and improving survival in endotoxin-challenged mice [35] . E5564 reduced the septic response after endotoxin challenge and, similar to E5531, improved survival after lethal intraperitoneal Escherichia coli challenge in mice made sensitive to endotoxin with BCG [35] . In combination, these studies support a potential role for lipid A analogues such as E5531 and E5564 in the treatment of gramnegative bacterial septic shock. However, antibodies to lipid A and recombinant bactericidal/permeability-increasing protein (rBPI21), which are also capable of inhibiting endotoxin, showed promise in early studies but failed in later clinical trials [31] [32] [33] . Although there may be several reasons for such failures, clinically relevant factors, such as the timing of treatment and the route of infection, could alter the dose of drug needed to be effective during gram-negative bacterial sepsis. In addition, the effects of E5564 have not yet been tested with live bacterial infection in an animal not previously sensitized to endotoxin. To investigate these issues, we studied the effects of differing doses of E5564 administered before or up to 3 h after E. coli challenge via either an intravascular or an extravascular route in an antibiotic-treated rat model of sepsis.
MATERIALS AND METHODS

Study Design
Sprague-Dawley rats (  ; table 1 60 ϫ 10 ϫ 10 9 cfu/kg]) in 0.5 mL of saline. On the basis of preliminary studies, these doses of bacteria were chosen for each route to produce a mortality rate of 60%-70% in combination with antibiotic therapy [36] . By use of a randomized study design, rats were treated with a bolus (0.5 mL) of E5564 from a range of doses chosen for study (0.03, 0.3, 1.0, 2.0, and 3.0 mg/kg) followed by 24-h infusions (10% of the bolus dose administered at 0.05 mL/h) or placebo (similar volumes of diluent only) via a syringe pump (PHD 2000; Harvard Apparatus). The bolus was given either 1 h before or 1 or 3 h after E. coli challenge. Total volumes of either drug or placebo were the same in all rats. Starting 6 h after E. coli challenge, all rats received ceftriaxone (100 mg/kg intramuscularly per day) for 4 days. Rats were observed every 2 h for 24 h, then every 4 h for 24 h, and, finally, every 8 h until the end of the study. Rats that were alive after 7 days were considered to be survivors. To further investigate the differing survival effects of E5564 with differing routes of infection, a subset of rats ( ) with arterial and central n p 732 venous catheters were treated with the highest dose of agent investigated 1 h after intravascular or intrabronchial challenge and then had hemodynamic, blood, and postmortem lung lavage measurements obtained at 4, 24, and 168 h.
Plasma, Blood, Lung Lavage, and Hemodynamic Measurements
At 4 and 24 h after E. coli challenge in randomly selected rats, arterial and venous catheters were connected via transducers to a hemodynamic monitoring system (BioSystem XA; BUXCO), to measure central venous pressure (CVP), mean arterial pressure (MAP), and heart rate (HR). After equilibration, continuous measurements of each parameter were obtained for a 2-min period, and the mean of the measurements for that period was recorded. Then, venous blood was obtained for determination of quantitative circulating bacterial counts, plasma TNFa levels, and plasma limulus amebocyte lysate (LAL) levels. Blood for quantitative circulating bacterial counts was collected in 1.5-mL isolator tubes (Dupont Medical Products), with serial dilutions of lysed samples plated for bacterial colony counts. Plasma TNF-a levels were measured using the WEHI 164 cell Figure 1 . Effect of E5564 on the proportion of Escherichia coli-challenged rats surviving over time. Shown are the effects of E5564 administered 1 h before (TϪ1) and 1 and 3 h after (T+1 and T+3) intravascular challenge or 1 h after extravascular challenge across a range of treatment doses (0.03-3.0 mg/kg bolus followed by 10% of the bolus dose infused hourly for 24 h), compared with those in placebo-treated control rats.
line. In addition, arterial blood was collected for blood-gas analysis (ABL-500) and for complete blood counts (ZB1; Coulter Electronic). Alveolar-to-arterial oxygen gradient (A-aO 2 ) and arterial base excesses were calculated using standard formulas. After hemodynamic measurements were obtained and blood was collected, rats were killed and lung lavage samples were obtained. Subsequent lung lavage cell counts and differentials, protein concentrations, and quantitative bacteria counts were determined. In randomly selected survivors, measurements similar to those obtained at 4 and 24 h (with the exception of hemodynamic measurements) were also obtained at 168 h.
Statistical Analysis
A Cox proportional hazards model or the Mantel-Haenszel x 2 test was used to compare the survival rates observed with E5564 administered at different times and doses and with placebo across different routes of infection. The effect that E5564 had on hemodynamic data was based on changes from baseline values, which were calculated immediately preceding treatment for individual rats. The effects that E5564 had on other laboratory parameters were based on differences after treatment only, because the quantity of blood required for samples limited the number that could be collected from each rat. Changes were compared using 4-way analysis of variance (ANOVA), , for all doses combined). B, P p .0001 Effect of delaying treatment in intravascularly challenged rats, for different doses of E5564. Across all treatment doses, E5564 was less beneficial when delayed ( , for loss of beneficial effect for delayed [1 or 3 h] vs. early [Ϫ1 h] treatment). C, Effect of increasing doses of E5564 administered P p .004 1 h after intravascular or extravascular (intrabronchial or intraperitoneal) challenge. An inverse pattern was found: increasing doses of E5564 were more beneficial for intravascular challenge, whereas increasing doses of E5564 were less beneficial for extravascular challenge.
taking into account the route of infection and the time and dose of treatment. Data that were not normally distributed were log transformed and analyzed, using nonparametric statistical analysis where appropriate. Although unlogged data are provided in the tables, the log-transformed data used in the analysis are provided in the figures. Two-way ANOVA was used to compare mean blood pressure, HR, and other laboratory measurements in survivors and nonsurvivors across the measurement . Effect (mean ‫ע‬ SE) of a high dose of E5564 (3.0 mg/kg bolus followed by 10% of the bolus dose infused hourly for 24 h) administered 1 h after lethal intravascular or extravascular (intrabronchial and intraperitoneal combined) Escherichia coli challenge on the hazard ratio for death in rats. E5564 was beneficial and significantly decreased ( ) the hazard ratio for intravascular challenge but was not P p .0001 beneficial and did not decrease the hazard ratio ( ) for extravascular P p .73 challenge (
, for the differing effects of E5564 on the hazard P p .001 ratio for intravascular vs. extravascular challenge).
time. In addition, the Tukey test was used where appropriate. Treatment effects ‫ע‬ SEs are shown and were calculated by subtracting the mean changes in the control group from the mean changes in the treatment group. Data are presented as means ‫ע‬ SEs, and was considered to be significant. P р .05 In the tables, normal values from uninfected rats tested previously in our laboratory are provided for reference.
RESULTS
Clinical Manifestations and Survival
By 4-6 h after both intravascular and extravascular (i.e., intrabronchial or intraperitoneal) E. coli challenge, the rats appeared weak and lethargic. In the control rats receiving placebo, mortality rates for infection via all 3 routes were 60%-70% (figure 1).
E5564 administered 1 h before intravascular E. coli challenge at all doses tested (0.3, 1.0, 2.0, and 3.0 mg/kg bolus followed by infusion) was beneficial and reduced the relative risk of death (mean ‫ע‬ SE hazard ratio for death figure 2A) . However, compared with treatment 1 h before intravascular challenge, when 3 of these same doses of E5564 (0.3, 2.0, and 3.0 mg/kg bolus followed by infusion) were administered 1 or 3 h after challenge, the effect of each was reduced ( , for the loss of beneficial effect P p .004 with E5564 averaged over the 3 doses with delayed treatment [1 or 3 h] vs. early treatment [Ϫ1 h] for intravascular challenge) (figure 2B). Despite this reduction in the effect of E5564 with delayed treatment, increasing the dose of E5564 administered 1 h after intravascular challenge (0.03, 0.3, or 3.0 mg/kg bolus followed by infusion) was associated with an increase in the beneficial effect, which was significant at the highest dose tested (mean ‫ע‬ SE hazard ratio for death , for increasing benefit with increasing dose of P p .0001 E5564) ( figure 2C, left panel) .
In contrast to intravascular E. coli challenge, the effect of differing doses of E5564 after extravascular challenge was inverted (figure 2C, left and right panels)-a low dose (0.03 mg/ kg bolus followed by infusion; mean ‫ע‬ SE hazard ratio for death 0.2 ‫ע‬ 0.12 P p .88 respectively) of E5564 administered 1 h after extravascular challenge was associated with a significant reduction in the hazard ratio for death ( , for the differing effects of high vs. P p .001 low doses of E5564 for extravascular vs. intravascular challenge) (figure 3).
Plasma, Blood, Lung Lavage, and Hemodynamic Measurements
To investigate why similar doses of E5564 had opposite effects on the relative risk of death between equivalently lethal intravascular and extravascular (i.e., intrabronchial) E. coli challenges, we examined blood and lung lavage laboratory measurements. In these experiments, rats, 1 h after intravascular or intrabronchial challenge that was designed to produce a 60%-70% mortality rate, were randomized to receive either the highest dose of E5564 tested (3.0 mg/kg bolus followed by infusion) or placebo, and laboratory measurements were then obtained at later time points, as described in Materials and Methods.
Plasma TNF-a levels. Plasma TNF-a levels were highest at 4 h and decreased at later time points (24 and 168 h) for both routes of infection, although initial levels were higher for intravascular challenge than for intrabronchial challenge (P p .04, for the effect of route of infection vs. time after infection on TNF-a levels) ( figure 4A ). E5564-treated rats had lower TNF-a levels at 4 h for both routes of infection and at 24 h for intravascular challenge but not extravascular challenge, compared with control rats, although none of these differences were significant ( ). P 1 .05 Circulating and lung lavage cell counts. Circulating total leukocyte, neutrophil, and platelet counts were significantly lower at 4 and 24 h than at 168 h in all treatment groups and Figure 4 . Log plasma tumor necrosis factor (TNF)-a (A) and limulus amebocyte lysate (LAL) (B) levels (mean ‫ע‬ SE) at 4 and 24 h after intravascular or extravascular (intrabronchial) Escherichia coli challenge in rats treated with placebo (control) or E5564. TNF-a levels were higher for both routes of infection early and decreased later, but they were higher for intravascular challenge than for extravascular challenge at 4 h ( , for the effect P p .04 of route of infection and time of treatment). E5564-treated rats had lower TNF-a levels at 4 h for both routes of infection and at 24 h for intravascular challenge but not for extravascular challenge, although none of these differences were significant ( ). At all time points studied, E5564 treatment P 1 .05 increased LAL levels. However, the increases produced by E5564 treatment were greater for extravascular challenge than for intravascular challenge ( , for the effect of E5546 on LAL level for extravascular vs. intravascular challenge at 4 and 24 h combined). P p .02 in the control group (table 2) . Of note, these cell counts were more decreased at 24 h for intrabronchial challenge than for intravascular challenge. In contrast, platelet counts were decreased less at 4 and 24 h for intrabronchial challenge than for intravascular challenge ( , for the differing effects of P p .001 route of infection vs. time after infection on each of these 3 parameters). Treatment with E5564 increased circulating total leukocyte, neutrophil, and platelet counts at 4 and 24 h after both intravascular and intrabronchial challenge ( , P p .04 P p .05, and , respectively) (table 2). P p .11 Lung lavage total leukocyte and neutrophil counts were greater at 4 and 24 h than at 168 h for both intravascular and intrabronchial challenge in all treatment groups and in the control group (table 3) . However, at all time points, these cell counts were greater for intrabronchial challenge than for intravascular challenge (
, for the effect of route of infection and time P p .001 after infection on each parameter). For both routes of infection, E5564 treatment was associated with reductions in lung lavage neutrophil counts at 4 h and with increases at 24 h. Overall, this increase was greater for intrabronchial challenge than for intravascular challenge but was not significantly different ( , P p .11 for the differing effects of E5564 treatment on lung lavage neutrophil counts from 4 to 24 h, comparing intrabronchial and intravascular challenge) (table 3) .
Plasma LAL levels. Plasma LAL levels were higher at 4 and 24 h than at 168 h for both intravascular and intrabronchial challenge in all treatment groups and in the control group ( , for the effect of time after infection on LAL levels) P p .001 (table 2) . E5564 treatment increased LAL levels at all time points studied. However, these increases were greater for intrabronchial challenge than for intravascular challenge ( , for P p .02 the effect of E5546 treatment on LAL level for intrabronchial vs. intravascular infection at 4 and 24 h combined) ( figure 4B ).
Blood and lung lavage bacteria counts. Blood and lung lavage bacteria counts were increased at 4 and 24 h, compared with those at 168 h, in all treatment groups and in the control group (tables 2 and 3). However, compared with those for intravascular challenge, blood bacteria counts were lower and Circulating cell and platelet counts, plasma tumor necrosis factor (TNF)-a levels, plasma limulus amebocyte lysate (LAL lung lavage bacteria counts were higher for intrabronchial challenge ( , for the effect of route of infection vs. time after P p .05 infection for each bacteria count). Although E5564 treatment was associated with reductions at 24 h in blood bacteria counts and at 4 and 24 h in lung lavage bacteria counts for intravascular challenge, for intrabronchial challenge, E5564 treatment was associated with increases in blood and lung lavage bacteria counts at both of these time points, although they were not significantly different ( , for the differing effect of E5564 P p .11 for intravascular vs. intrabronchial challenge at 4 and 24 h) ( figure 5A and 5B).
Hemodynamic measurements.
HRs were lower at 4 h than at 24 h and were lower for intrabronchial challenge than for intravascular challenge in all treatment groups and in the control group ( , for the effect of route of infection and P p .005 time after infection on HR) (table 4). E5564 treatment decreased HRs and CVP at 4 and 24 h during intrabronchial challenge, compared with those during intravascular challenge, although not significantly ( and , re-P p .08 P p .16 spectively, for the differing effect of E5564 treatment on intrabronchial vs. intravascular challenge at 4 and 24 h combined). MAP, although low for both routes of infection (com- Figure 5 . Log blood (A) and lung lavage (B) bacteria counts (mean ‫ע‬ SE) at 4 and 24 h after intravascular or extravascular (intrabronchial) Escherichia coli challenge in rats treated with placebo (control) or E5564. Although E5564 treatment was associated with reductions in blood bacteria counts at 24 h and in lung lavage bacteria counts at 4 and 24 h for intravascular challenge, for extravascular challenge, E5564 treatment was associated with increases in blood and lung lavage bacteria counts at both of these time points ( , for the differing effect of E5564 for intravascular vs. extravascular P p .11 infection at 4 and 24 h).
pared with that in the control rats), did not differ significantly ( ) between any group. P 1 .05
Other laboratory parameters. Arterial pH was lower and base excess, lactate, A-aO 2 , and hemoglobin levels were higher at 4 and 24 h than at 168 h in all treatment groups and in the control group ( , for all parameters) (table 5). Compared P ! .05 with those for intravascular challenge, A-aO 2 and hemoglobin levels were higher for intrabronchial challenge ( , for both P ! .05 parameters). E5564 treatment did not significantly alter (P 1 ) any of the other parameters at any time point during the .20 experiment.
DISCUSSION
The present study is the first to demonstrate potential beneficial effects on survival with E5564 during live bacterial infection in a normal host. Previous studies testing the inhibition of lipid A by use of this agent or the related one, E5531, via intraperitoneal E. coli challenge were performed in mice that had been pretreated with BCG [31, 32] ; this pretreatment increases the sensitivity of rats to the toxic inflammatory effects of LPS [32] .
In the present study, however, the beneficial effects of E5564 were not uniform and appeared to be altered by several clinically relevant parameters.
Both low and high doses of E5564 increased survival when administered before intravascular E. coli challenge. The benefit of E5564 was reduced, however, by treatment that was delayed as little as 1 h after intravascular challenge, suggesting that the activation of lethal pathogenic mechanisms by lipid A occurs rapidly with this challenge. However, that high doses of E5564 were still beneficial when administered 1 h after intravascular challenge suggests that the administration of sufficient competitive inhibitor still alters these mechanisms during intravascular infection. This delayed-treatment effect is consistent with findings in an LPS-infused animal model, in which E5531 was found to be effective if administered up to 1 h after challenge but not later [33] .
The same high doses of E5564 that were beneficial for intravascular challenge, however, were not beneficial for extravascular challenge-survival was not improved, and both HR and CVP were lower. There may be several reasons for this difference. It is possible that the effects of higher doses of E5564 on the inhibition of inflammatory tissue injury and host defense, although favoring the former for intravascular challenge, negated each other for extravascular challenge. E5564 treatment reduced early increases in TNF-a levels for both routes of infection. Although not significant, this effect of E5564 is very consistent with the findings of another study [37] . The early decreases in plasma TNF-a levels after the administration of high doses of E5564 observed in the present study may, in turn, have limited endothelial and leukocyte adhesion molecule expression and the leukocyte margination and extravascular recruitment associated with it [38] . In fact, for both routes of infection, the administration of E5564 in high doses increased the circulating neutrophil count at 4 and 24 h combined but decreased the lung lavage neutrophil count (albeit not significantly) at 4 h. Although the neutrophil may not play a predominant role in microbial clearance during intravascular infection, it is essential during extravascular infection [30, 38, 39] . Thus, in our model, the inhibition of neutrophil margination and the recruitment of neutrophils from the vascular space via high doses of E5564 may have limited the host defense during extravascular challenge but not during intravascular challenge. Consistent with the variable effects of E5564 in our model, both TNF-a and neutrophil adhesion molecule-directed antibodies have also been shown to have similar differing effects during intravascular and extravascular infectious chal-lenges [38, 40, 41] . The inhibition of neutrophil trafficking, if present in our study, was lost over time, because there was a greater increase in lung lavage neutrophil counts at 24 h during extravascular challenge than during intravascular challenge. One could also postulate, however, that E5564 administered at high doses via an intravascular route when the bacterial load is primarily in an extravascular space has a proinflammatory agonist effect. Despite reductions in plasma TNF-a levels at 4 h for both routes of infection, at 24 h, TNF-a levels were increased for extravascular challenge but not for intravascular challenge. Furthermore, at this same time point, there was an increase in lung lavage neutrophil counts during extravascular challenge, compared with that during intravascular challenge. Finally, although E5564 can activate the limulus assay, plasma LAL levels for similar treatment doses were greater during extravascular challenge than during intravascular challenge [37] . In combination, these increases in TNF-a levels, later lung lavage neutrophil counts, and LAL levels support a greater increase in the potential stimulatory effects of E5564 with higher doses when the bacterial source of lipid A is mostly extravascular.
Importantly, however, reducing the dose of E5564 for extravascular infection increased its efficacy. This dose reduction presumably resulted in beneficial anti-inflammatory effects that were greater than any adverse effects. Other sepsis studies have also suggested that the dose of anti-inflammatory agents must be reduced to achieve efficacy [42] [43] [44] [45] [46] . During a clinical trial in which sepsis was typically caused by extravascular infection, low-dose, but not high-dose, corticosteroids appeared to be beneficial [43] . In fact, higher doses were associated with more infection complications. Also, in another trial, a potentially harmful effect of soluble TNF-a receptor appeared to be decreased when the dose of this agent was reduced [44] . Under different but analogous circumstances, we found that fixed doses of several different mediator-specific anti-inflammatory agents, although beneficial for highly lethal infectious challenges, became less beneficial and then harmful as the challenge dose and the associated inflammatory response were reduced [36, 45] . This loss of benefit in subjects with sepsis who were less severely ill was also found clinically for activated protein C [46] . As with these other therapies that alter the host response during infection and sepsis, determination of the clinically correct dose of E5564 for the appropriate septic population may depend on several factors.
A clinical trial of E5564 in patients with sepsis is ongoing [42] . Previous clinical-sepsis trials that tested antibodies against lipid A as well as rBPI21, both of which bind to and inhibit endotoxin, failed to show significant beneficial effects on survival [47] [48] [49] [50] . It is not known whether this was because these previously tested agents did not have the necessary bioactivity or because methodological or trial-design flaws were present-or both. However, in the case of E5564, the results of previous preclinical testing as well as investigations in healthy human volunteers indicate that this agent has substantial inhibitory bioactivity against lipid A. The findings of the present study, although consistent with those of previous ones, also point to 2 factors (timing of treatment and route of infection) that may have to be accounted for when E5564 is administered during bacterial sepsis. It is not clear whether these 2 factors as we have studied them in E. coli-challenged rats accurately reflect the variable conditions that would be encountered clinically. Nonetheless, regardless of whether this agent is clinically effective, the present study suggests several ways in which the dosing of lipid A analogues might be adjusted to increase their efficacy.
In conclusion, the timing of treatment and the route of infection altered the effective dosing of E5564 in our rat model of E. coli sepsis. The variable effects between intravascular and extravascular challenge may reflect the divergent influence of LPS signaling on the innate immune response and inflammatory tissue injury. Depending on the site of infection, triggering host defense or inhibiting inflammation may be more important. Although there are many differences between the animal model used in the present study and human sepsis, our findings suggest that E5564, to be most effective, may have to be given as early as possible and that the therapeutic dosing may have to be adjusted upward if the infection is predominantly intravascular and downward if it is predominantly extravascular.
